Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Bioasis Technologies Inc. V.BTI

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factors and the xB3™ platform, a proprietary technology for the delivery of therapeutics across the blood brain barrier and the treatment of CNS disorders in areas of high unmet medical need. The in-house development programs are designed to... see more

TSXV:BTI - Post Discussion

View:
Post by prophetoffactz on Jan 13, 2023 5:14pm

20-day VWAP

  • "If the 20-day VWAP prior to Closing is less than $0.90, the Company may terminate the Private Placement without penalty; and" Midatech
BTI's shareholder meeting is Feb. 3. While not a TSX-V company and it didn't have the international component RECP was taken private and was listed on the TSX. It received shareholder approval on October 21, 2022. The transaction was closed one week later October 28, 2022. November 1, 2022 was RECP's last day of trading on the TSX.

If BTI's transaction is completed one week after the shareholder vote on Feb. 3 that would take us to Feb. 10. That would mean the 20-day VWAP could begin today given Monday is a holiday in the US. Need to know the specifics for the calculation. Maybe clarity is in the documents.

Midatech shareholder approval.
BTI shareholder approval.
J&J xB3 option expiration Jan. 31.

Could all significantly impact the 20-day VWAP. 

Midatech's current price of $.65 needs big improvement. 
The S&P Biotech ETF is up about 8% this year.
Midatech's CEO said he could have put together a syndicate instead of the Armistice financing. With the improvment in the markets maybe there are options should the improvement last. They better get to work and defend the deal starting next week assuming the above. 


 
Comment by narmac on Jan 13, 2023 6:55pm
,,Good news then,,,,,,the deal is clearly being frowned upon by the Market,,,,,,,Midatech shareholders might also give the middle finger to the deal,,,,who would blame them either!,, If things keep going this way I cross my fingers the larger shareholders combine to put forth a plan B...I figure most of us little minions would support a plan B,,it would undoubtedly be a step ahead of plan A ...more  
Comment by fuzzyjr on Jan 13, 2023 7:12pm
".I figure most of us little minions would support a plan B,,it would undoubtedly be a step ahead of plan A" just need to see this plan b & preferably not sitting or waiting on something that may or may not happen ... "two years down the road!!
Comment by Boomskid on Jan 13, 2023 7:21pm
I doubt that there is any meaning to the J&J option deadline of January 31, 2023. If two parties want to get a deal done, they'll get it done. Whatever J&J may have, they don't have xB3 so if it's valuable to them, they'll all wait.  About Plan B, ask GD how long shareholders have after Feb 3 to save the xB3 IP from foreclosure by Lind if Bioasis shareholders vote ...more  
Comment by narmac on Jan 13, 2023 7:56pm
Hummm,,based on this deal,,if one asked management would we get a truthful answer?...who would actually know,,the complication of the deal is enuff to confuse the best of readers,,,,intende of course,,,,,,,,,..All we have been told is vote yes or we implode!!,,,no update from anyone who visisted the road show last month,,,the common shareholder is expected to be confused and kept at arms length ...more  
Comment by fuzzyjr on Jan 13, 2023 8:19pm
I hear ya Narmac & appreciate & feel the frustration &  b. S ...  T /dilution of plan A but realistically we have seen nothing resembling any sort of a decent plan b or any plan B for that matter that we can back.
Comment by prophetoffactz on Jan 13, 2023 8:26pm
"I doubt that there is any meaning to the J&J option deadline of January 31, 2023." While the two parties can do anything they want when an option with a deadline is negotiated the deadline generally should matter. Someone wanted it. If J&J doesn't exercise the option by the deadline perhaps BTI could take the data and shop it for better terms the research having been de ...more  
Comment by Itistoo on Jan 13, 2023 10:41pm
Who cares.. this story is over, let it go and move to another stock. You guys are unreal, so attached to this pos looking for glimmers of hope.. this company is dead.. this deal is dead, the company being merged with is on it's way to death.. there is nothing good here, why alwaste your time.. just another scam biotech, a dime a dozen.
Comment by narmac on Jan 14, 2023 8:46am
,,Options,,,I guess there are options out there for us,,,,,hummm,,the more one dives into the sector and situation the more options become evident,,,,,we need to get off our back sides and ask questions and poke the bear as they say!!! Booooooooooyaaaaaaaaaaa!!!,,,,Baby!!!!!!
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities